Caricamento...
Vismodegib for periocular basal cell carcinoma: an international multicentre case series
INTRODUCTION: Vismodegib (Erivedge, Genentech) is a first-in-class inhibitor of the hedgehog (Hh) pathway, which is licensed for use in locally advanced basal cell carcinoma (BCC) and metastatic BCC. The National Institute for Health and Care Excellence withdrew recommendation for use of vismodegib...
Salvato in:
| Pubblicato in: | Eye (Lond) |
|---|---|
| Autori principali: | , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784971/ https://ncbi.nlm.nih.gov/pubmed/31996838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-020-0778-3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|